- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01121783
The Effect of Lactisole on the Responses to Glucose Solution
May 10, 2010 updated by: Northern Care Alliance NHS Foundation Trust
Study of the Effect of Lactisole on the Responses to Intragastric Glucose Solution
The purpose of the study is to determine whether the sweet taste receptors in the gut are involved in sensing sweet substances and controlling appetite and the amount we eat.
Lactisole is a substance commonly used in food products to reduce the perceived sweetness of certain sugars and sweeteners.
The aim of this study is to investigate whether the responses to a glucose solution, intragastrically administered to healthy male and female volunteers, is affected by the presence of lactisole in the gut.
Understanding the mechanisms by which nutrients are initially detected in the gut and how they influence food intake is critical to the development of novel food products that could reduce food consumption.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Obesity is epidemically prevalent and a major risk factor for chronic diseases making it fundamental to understand the pathways controlling food intake.
During the course of a meal and afterwards the gut and brain communicate to control how full the eater feels and thus control the amount of food eaten.
The information relayed from the gut to the brain regarding ingested nutrients is of increasing importance and understanding the mechanisms by which nutrient molecules are initially detected in the gut and how they signal to the brain to influence food intake is critical to the development of novel food products that could induce fullness and reduce food consumption.
Increasing our understanding of how nutrients are sensed in the gut and how this may influence subsequent food intake provides promising targets for obesity prevention and treatment.
Recent discoveries have shown that sweet taste receptors similar to those located in the tongue are present in the gut.
It is suggested that theses receptors are involved in the way nutrients are sensed and may play an important role in appetite control and food intake.
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Manchester, United Kingdom
- Recruiting
- Salford Royal NHS Foundation Trust
-
Contact:
- Nerys M Astbury, Bsc. MMedSci, PhD
- Phone Number: 0161 206 1447
- Email: nerys.astbury@manchester.ac.uk
-
Contact:
- Charlotte E Bryant, Bsc, MMedSci
- Phone Number: 0161 2061447
- Email: charlotte.bryant@postgrad.manchester.ac.uk
-
Principal Investigator:
- David Thompson, FRCP, fMedSci
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged between 18-45 years
- BMI between 18-25kg/m2
- General good health
Exclusion Criteria:
- Underweight or Overweight (Body Mass Index <19 or >25 kg.m-2)
- Females who are pregnant or breastfeeding
- Currently taking medication (except females taking oral contraceptive)
- Smokers
- Currently dieting or have experienced a weight change +/- 3kg in past 6 months
- Metabolic disorders (eg. Type 2 diabetes)
- History of gastrointestinal disorders
- Participation in other research in past 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Lactisole-Glucose
|
A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube.
After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
|
Active Comparator: Lactisole-water
|
A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube.
After 15 minutes tap water will be administered as a bolus via the intragastric tube.
A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube.
After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube.
After 15 minutes tap water is administered as a bolus via intragastric tube.
|
Placebo Comparator: Water-Glcuose
|
A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube.
After 15 minutes tap water will be administered as a bolus via the intragastric tube.
A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube.
After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube.
After 15 minutes tap water is administered as a bolus via intragastric tube.
|
Placebo Comparator: Water-Water
|
A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube.
After 15 minutes tap water will be administered as a bolus via the intragastric tube.
A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube.
After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube.
After 15 minutes tap water is administered as a bolus via intragastric tube.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood glucose
Time Frame: Blood samples will be collected at baseline and 5, 15 and 30 minute intervals until 150 minutes after the glucose infusion
|
Blood samples will be collected at baseline and 5, 15 and 30 minute intervals until 150 minutes after the glucose infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective appetite ratings
Time Frame: 30 minute intervals
|
Participants will be asked to complete visual analogue scale questionnaire (VAS) up to a total of 6 times for the duration of each study
|
30 minute intervals
|
Gastric emptying rate
Time Frame: Breath samples are collected at 5, 15 and 30 minute intervals up to a total of 10 times until 150 minutes
|
In order to assess gastric emptying, a stable isotope of carbon, in the form of 13Csodium acetate will be added to the test meal.
This is absorbed only once it has passed through the stomach into the duodenum.
It is then metabolised and exhaled in the breath as 13Clabelled carbon dioxide (CO2) where it can be measured.
|
Breath samples are collected at 5, 15 and 30 minute intervals up to a total of 10 times until 150 minutes
|
Energy intake
|
Energy intake will be assessed by an ad libitum test meal provided at the end of each study and food diaries completed for the remainder of the day
|
|
Gut hormones
Time Frame: Blood samples will be collected at baseline, 5, 15 and 30 minute intervals until 150 minutes after glucose infusion.
|
Blood samples will be processed to examine hormone levels of GLP-1, PYY, and insulin.
|
Blood samples will be collected at baseline, 5, 15 and 30 minute intervals until 150 minutes after glucose infusion.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: David Thompson, FRCP, fMedSci,, University of Manchester
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Anticipated)
May 1, 2011
Study Completion (Anticipated)
May 1, 2011
Study Registration Dates
First Submitted
May 10, 2010
First Submitted That Met QC Criteria
May 10, 2010
First Posted (Estimate)
May 12, 2010
Study Record Updates
Last Update Posted (Estimate)
May 12, 2010
Last Update Submitted That Met QC Criteria
May 10, 2010
Last Verified
March 1, 2010
More Information
Terms related to this study
Other Study ID Numbers
- Lactisole
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Glucose
-
Wageningen University and ResearchCompletedGlucose, Low Blood | Glucose, High BloodNetherlands
-
Inland Norway University of Applied SciencesUniversity of OsloCompletedBlood Glucose | Blood Glucose Related VariablesNorway
-
Ingredion IncorporatedKGK Science Inc.CompletedGlucose, Low Blood | Glucose, High Blood | Meals
-
Matthew GroutCompletedMood | Cognitive Performance | Glucose, Low Blood | Glucose, High BloodUnited Kingdom
-
Matthew GroutCompletedDiet Modification | Mood | Glucose, Low Blood | Glucose, High Blood
-
Weizmann Institute of ScienceCompletedGlucose Intolerance | Glucose, Low Blood | Glucose, High BloodIsrael
-
University of ReadingRecruiting
-
University of ManitobaAgriculture and Agri-Food CanadaCompleted
-
University of CopenhagenDaniscoCompleted
-
Edwards LifesciencesDexCom, Inc.; Medical Device Consultants, Inc.Completed
Clinical Trials on Lactisole
-
University GhentVIBCompleted
-
University Hospital, Basel, SwitzerlandCompletedPhysiological Satiation MechanismsSwitzerland
-
University Hospital, Basel, SwitzerlandCompletedTaste Disorder, Secondary, SweetSwitzerland
-
University Hospital, Basel, SwitzerlandCompletedAppetite and General Nutritional Disorders | Hormone ReplacementSwitzerland
-
University Hospital, Basel, SwitzerlandCompletedTaste Disorder, Primary, SweetSwitzerland
-
AdventHealth Translational Research InstituteCompletedObesityUnited States
-
University Hospital, Basel, SwitzerlandCompletedExploratory BehaviorSwitzerland
-
University of ViennaCompletedHunger | Blood Glucose, LowAustria